Lmr Partners LLP Lineage Cell Therapeutics, Inc. Transaction History

Lmr Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $100,074 - $127,594	83,395 New	83,395 $125,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $50,100 - $72,020	44,733 New	44,733 $71,000
Q2 2021 Aug 16, 2021	SELL	$2.17 - $3.0 $156,660 - $216,582	-72,194 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $127,783 - $223,801	72,194 New	72,194 $170,000
Q4 2020 Feb 16, 2021	SELL	$0.95 - $1.83 $38,078 - $73,351	-40,083 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$0.75 - $1.09 $5,305 - $7,710	-7,074 Reduced 15.0%	40,083 $38,000
Q2 2020 Aug 14, 2020	BUY	$0.71 - $1.18 $33,481 - $55,645	47,157 New	47,157 $41,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $91.7M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.